BEAM News and Press, Beam Therapeutics Inc. From 05/16/23

2023-05-16 05:50:00 ET Cathie Wood looks for stocks that are leading innovators. But the stocks that fit that mold aren't always leaders when it comes to delivering huge returns over the short term. On the contrary, quite a few of the stocks in Wood's Ark Invest portfolios have been big...

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president of Beam, plans to participate in a fireside chat during the...

2023-05-10 08:47:10 ET Beam Therapeutics press release ( NASDAQ: BEAM ): Q1 GAAP EPS of -$1.33 in-line. Revenue of $24.2M (+187.1% Y/Y) beats by $8.56M . For further details see: Beam Therapeutics GAAP EPS of -$1.33 in-line, revenue of $24.2M beats by $8.56M

Focused on Executing Three Strategic Pillars – Hematology, Immunology/Oncology and Genetic Diseases – Potential for Long-Term Pipeline Growth and Sustained Impact on Patient Lives Multiple Sites Activated and Additional Patients Enrolled in BEACON Clinical Trial of BEAM-10...

2023-05-02 12:25:44 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cathie Wood invests in speculative stocks that don’t always pan out, as 2022 showed. The chief of Ark Investment Management watched her firm outperform in 2021, though last year saw a sh...

2023-05-02 05:53:00 ET If there's one word you could use to describe the kinds of stocks that Cathie Wood buys, it would be "innovative." In fact, three of her ARK Invest exchange-traded funds (ETFs) include the word "innovation" in their names. Some of the ARK Invest portfolio position...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The next big things for investors are always around the corner. As investors say goodbye to the 2022 bear market, we look forward to what could be an excellent 2023. Indeed, while this coming year will likely provide investor...

CAMBRIDGE, Mass., Dec. 10, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new preclinical data from its Engineered Stem Cell Antibody Paired Evasion (ESCAPE) conditioning appr...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Editor’s Note: On Tuesday, Dec. 13, at 4 p.m. Eastern time , Louis Navellier, Eric Fry, and Luke Lango are gathering for a special event – the Early Warning Summit – to give you their investing ga...

Summary Beam Therapeutics announced the recruitment of its first BEACON trial patient in the middle of November 2022. BEAM's announcement was followed by Editas Medicine's declaration of positive safety and efficacy data from its first two patients enrolled and treated under the Ruby tr...